Changes in intracellular folate metabolism during high-dose methotrexate and Leucovorin rescue therapy in children with acute lymphoblastic leukemia.
Adolescent
Antidotes
/ administration & dosage
Child
Child, Preschool
Erythrocytes
/ drug effects
Female
Folic Acid
/ blood
Folic Acid Antagonists
/ administration & dosage
Homocysteine
/ blood
Humans
Infant
Leucovorin
/ administration & dosage
Male
Metabolic Networks and Pathways
Methotrexate
/ administration & dosage
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ blood
Prospective Studies
Vitamin B 12
/ blood
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
08
04
2019
accepted:
09
08
2019
entrez:
19
9
2019
pubmed:
19
9
2019
medline:
17
3
2020
Statut:
epublish
Résumé
Methotrexate (MTX) is an important anti-folate agent in pediatric acute lymphoblastic leukemia (ALL) treatment. Folinic acid rescue therapy (Leucovorin) is administered after MTX to reduce toxicity. Previous studies hypothesized that Leucovorin could 'rescue' both normal healthy cells and leukemic blasts from cell death. We assessed whether Leucovorin is able to restore red blood cell folate levels after MTX. We prospectively determined erythrocyte folate levels (5-methyltetrahydrofolate (THF) and non-methyl THF) and serum folate levels in 67 children with ALL before start (T0) and after stop (T1) of HD-MTX and Leucovorin courses. Erythrocyte folate levels increased between T0 and T1 (mean ± SD: 416.7 ± 145.5 nmol/L and 641.2 ± 196.3 nmol/L respectively, p<0.001). This was due to an increase in 5-methyl THF levels (mean increase: 217.7 ± 209.5 nmol/L, p<0.001), whereas non-methyl THF levels did not change (median increase: 0.6 nmol/L [-9.9-11.1], p = 0.676). Serum folate levels increased between T0 and T1 (median increase: 29.2 nmol/L [32.9-74.0], p<0.001). Results were not significantly affected by age, sex, ALL immunophenotype and MTHFR c.677C>T genotype. Intracellular folate levels accumulate after HD-MTX and Leucovorin therapy in children with ALL, suggesting that Leucovorin restores the intracellular folate pool. Future studies are necessary to assess concomitant lower uptake of MTX.
Sections du résumé
BACKGROUND
Methotrexate (MTX) is an important anti-folate agent in pediatric acute lymphoblastic leukemia (ALL) treatment. Folinic acid rescue therapy (Leucovorin) is administered after MTX to reduce toxicity. Previous studies hypothesized that Leucovorin could 'rescue' both normal healthy cells and leukemic blasts from cell death. We assessed whether Leucovorin is able to restore red blood cell folate levels after MTX.
METHODS
We prospectively determined erythrocyte folate levels (5-methyltetrahydrofolate (THF) and non-methyl THF) and serum folate levels in 67 children with ALL before start (T0) and after stop (T1) of HD-MTX and Leucovorin courses.
RESULTS
Erythrocyte folate levels increased between T0 and T1 (mean ± SD: 416.7 ± 145.5 nmol/L and 641.2 ± 196.3 nmol/L respectively, p<0.001). This was due to an increase in 5-methyl THF levels (mean increase: 217.7 ± 209.5 nmol/L, p<0.001), whereas non-methyl THF levels did not change (median increase: 0.6 nmol/L [-9.9-11.1], p = 0.676). Serum folate levels increased between T0 and T1 (median increase: 29.2 nmol/L [32.9-74.0], p<0.001). Results were not significantly affected by age, sex, ALL immunophenotype and MTHFR c.677C>T genotype.
CONCLUSION
Intracellular folate levels accumulate after HD-MTX and Leucovorin therapy in children with ALL, suggesting that Leucovorin restores the intracellular folate pool. Future studies are necessary to assess concomitant lower uptake of MTX.
Identifiants
pubmed: 31527879
doi: 10.1371/journal.pone.0221591
pii: PONE-D-19-10004
pmc: PMC6748431
doi:
Substances chimiques
Antidotes
0
Folic Acid Antagonists
0
Homocysteine
0LVT1QZ0BA
Folic Acid
935E97BOY8
Vitamin B 12
P6YC3EG204
Leucovorin
Q573I9DVLP
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0221591Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Rheumatology (Oxford). 2002 Jun;41(6):658-65
pubmed: 12048292
Cancer Chemother Pharmacol. 1992;31(3):217-22
pubmed: 1464159
Br J Haematol. 2006 Mar;132(5):623-9
pubmed: 16445837
Clin Chem. 2006 Apr;52(4):692-700
pubmed: 16455868
Clin Chem Lab Med. 2006;44(4):450-9
pubmed: 16599840
Clin Chem Lab Med. 2006;44(8):987-90
pubmed: 16879066
Leukemia. 2006 Nov;20(11):1955-62
pubmed: 16990760
J Nutr Biochem. 2007 Oct;18(10):693-9
pubmed: 17418558
J Natl Cancer Inst. 1991 Dec 18;83(24):1806-12
pubmed: 1744924
J Am Coll Nutr. 2007 Oct;26(5):453-5
pubmed: 17914133
Eur J Cancer. 1991;27(8):1006-9
pubmed: 1832883
Int J Med Sci. 2009;6(4):156-9
pubmed: 19421340
Cancer Res. 1991 Feb 1;51(3):828-35
pubmed: 1988122
J Clin Oncol. 2009 Dec 10;27(35):5972-8
pubmed: 19901119
Leukemia. 2010 Feb;24(2):309-19
pubmed: 20016528
Nat Rev Rheumatol. 2010 Mar;6(3):175-8
pubmed: 20197777
Eur J Clin Pharmacol. 1990;39(4):377-83
pubmed: 2076721
J Clin Oncol. 2011 Feb 10;29(5):551-65
pubmed: 21220611
J Pediatr Hematol Oncol. 2012 Jan;34(1):e1-7
pubmed: 21364468
Br J Clin Pharmacol. 2012 Jan;73(1):106-14
pubmed: 21707700
Rev Endocr Metab Disord. 2012 Jun;13(2):109-19
pubmed: 22418620
Anal Bioanal Chem. 2013 Feb;405(5):1673-81
pubmed: 23239179
Clin Chem Lab Med. 2013 Mar 1;51(3):607-16
pubmed: 23241610
Eur J Clin Pharmacol. 2013 Sep;69(9):1641-9
pubmed: 23660772
Zebrafish. 2013 Sep;10(3):326-37
pubmed: 23758124
Cancer Chemother Pharmacol. 2013 Aug;72(2):369-78
pubmed: 23760811
Lancet Oncol. 2014 Jan;15(1):35-47
pubmed: 24314616
NCI Monogr. 1987;(5):17-26
pubmed: 2448654
Arthritis Rheumatol. 2014 Dec;66(12):3476-85
pubmed: 25186097
Pharmacogenomics J. 2015 Jun;15(3):248-54
pubmed: 25348617
J Clin Oncol. 2016 Aug 1;34(22):2591-601
pubmed: 27269950
Br J Cancer. 1989 Apr;59(4):627-30
pubmed: 2785400
Cancer Chemother Pharmacol. 1989;23(6):353-7
pubmed: 2785439
Cancer Res. 1989 Nov 1;49(21):5879-83
pubmed: 2790801
Arthritis Rheum. 1988 Jul;31(7):906-8
pubmed: 3260783
Cancer Chemother Pharmacol. 1987;19(4):319-25
pubmed: 3496173
NCI Monogr. 1987;(5):41-5
pubmed: 3501545
Lancet. 1981 Aug 15;2(8242):337-40
pubmed: 6115113
Br J Haematol. 1981 Nov;49(3):355-60
pubmed: 6170307
J Pediatr. 1984 Jan;104(1):131-3
pubmed: 6581287
J Clin Oncol. 1993 May;11(5):827-33
pubmed: 8487046
J Pharmacol Exp Ther. 1997 Sep;282(3):1305-11
pubmed: 9316839